Diniz, Juliana B <br/><br/>
The impact of comorbid body dysmorphic disorder on the response to sequential pharmacological trials for obsessive-compulsive disorder.  [electronic resource] 

 -  Journal of psychopharmacology (Oxford, England)  Jun 2014 
 - 603-11 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>1461-7285 
<br/><br/><label>Standard No.: </label>10.1177/0269881113512042  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Antidepressive Agents, Second-Generation--adverse effects<br/>Antidepressive Agents, Tricyclic--adverse effects<br/>Antipsychotic Agents--adverse effects<br/>Body Dysmorphic Disorders--diagnosis<br/>Brazil<br/>Clomipramine--adverse effects<br/>Comorbidity<br/>Drug Therapy, Combination<br/>Female<br/>Fluoxetine--adverse effects<br/>Humans<br/>Male<br/>Obsessive-Compulsive Disorder--diagnosis<br/>Prospective Studies<br/>Quetiapine Fumarate--adverse effects<br/>Risk Factors<br/>Treatment Outcome